MHRA draft guidance on the licensing of biosimilar products out for consultation

This new draft guidance is based on the current EMA biosimilar guidance, with additional details about UK reference products, the lack of requirement for in vivo studies in animals and the changes in the requirement for a comparative efficacy trial in most cases.

Source:

Medicines and Healthcare products Regulatory Agency